NASDAQ:ADGI
Delisted

Adagio Therapeutics Stock News

etoro logo Buy ADGI
*Your capital is at risk
$2.47
+0.0900 (+3.78%)
At Close: Jan 27, 2023
Adagio Therapeutics Inc (NASDAQ:ADGI) Investment analysts at Jefferies Financial Group boosted their FY2021 earnings per share estimates for shares of Adagio Therapeutics in a research note issued on Monday, November 15th. Jefferies Financial Group analyst M. Yee now expects that the company will post earnings of ($1.88) per share for the year, up from []
Adagio Therapeutics Inc (NASDAQ:ADGI) Jefferies Financial Group boosted their FY2023 earnings per share (EPS) estimates for Adagio Therapeutics in a report issued on Monday, November 15th. Jefferies Financial Group analyst M. Yee now forecasts that the company will post earnings of $5.34 per share for the year, up from their prior estimate of $5.33. []
Related Stocks: BIIB , IKNA , ABBV , GLPG , SIBN , LUNG , ADGI , ZBH , HCA , ERAS , SGEN , CTKB , AUPH , ASND , TRIL , ARCT , ALXN , ALEC ,
Related Stocks: MNTV , PRPL , FTDR , LOPE , ACVA , ALLK , ADGI , NABL , SWI , SRAD , STER , ALIT , PFPT , IT , WIX , KMT , FBRX , MASI ,
Related Stocks: ALPN , IMGO , ADGI , ICVX ,
Related Stocks: RPID , ADGI , NUVL , TNGX , ARYE , KYMR , BCTG ,
Related Stocks: INBX , BNTX , ADGI , VIR , FULC , AVTE , BEAM , EPIX , KROS , RLAY , GBIO ,

Adagio Therapeutics EPS misses by $0.23

11:44am, Monday, 15'th Nov 2021 Seeking Alpha
WALTHAM, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of an
Data to be presented at the 2021 ISIRV-WHO Virtual Conference Data to be presented at the 2021 ISIRV-WHO Virtual Conference
Adagio Therapeutics Inc (NASDAQ: ADGI) has announced new data from its COVID-19 antibody program.  Related Link:   Adagio Therapeutics To Expand Late-Stage COVID-19 Antibody Trial.
ADG20 Continues to be Well Tolerated in Healthy Volunteers with Prolonged Half-Life and Serum Virus Neutralization Activity Observed out to Six Months in Ongoing Phase 1 Study
New Data Supporting Potential of ADG20 for Both the Treatment and Prevention of COVID-19 to be Presented at IDWeek 2021
Adagio Therapeutics Inc (NASDAQ: ADGI) announced that the independent data monitoring committee (IDMC) has recommended expanding the ADG20 EVADE Phase 2/3 trial for COVID-19. The IDMC has supported
Find out what these industry favorites are doing to impress investors.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE